XML 46 R29.htm IDEA: XBRL DOCUMENT
v3.20.2

Collaboration Agreements and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail) - USD ($) $ in Thousands |  | 1 Months Ended | 6 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | ---
Jul. 30, 2013 | Apr. 30, 2020 | Dec. 31, 2019 | Jun. 30, 2020 | Dec. 31, 2015 | Mar. 31, 2020 | Jun. 30, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Unbilled contract asset |  |  | $ 180,000 | $ 0 |  |  |
AstraZeneca Agreements [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Transaction price and allocated to performance obligations |  |  |  |  |  |  | $ 50,000
Revenue during period from performance obligations |  |  | 42,400 | 400 |  |  |
Unbilled contract asset |  |  |  |  |  | $ 50,000 |
AstraZeneca Agreements [Member] | U.S./RoW [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Upfront, non-contingent, non-refundable and time-based payments | $ 374,000 |  |  |  |  |  |
Potential milestone payments | 875,000 |  |  |  |  |  |
Commercial sales milestone | 325,000 |  |  |  |  |  |
Aggregate consideration received |  |  |  | 439,000 |  |  |
Unbilled contract asset |  |  | 50,000 |  |  |  |
AstraZeneca Agreements [Member] | U.S./RoW [Member] | Clinical and Development Milestone [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Potential milestone payments | 65,000 |  |  |  |  |  |
AstraZeneca Agreements [Member] | U.S./RoW [Member] | Regulatory Milestone [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Potential milestone payments | 325,000 |  |  |  |  |  |
AstraZeneca Agreements [Member] | U.S./RoW [Member] | Deferred Approval Milestone [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Potential milestone payments | 160,000 |  |  |  |  |  |
AstraZeneca Agreements [Member] | U.S./RoW [Member] | Development Milestones [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Receipt of development milestone payment |  |  |  |  | $ 15,000 |  |
AstraZeneca Agreements [Member] | U.S./RoW [Member] | NDA Submission Milestone [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Receipt of development milestone payment |  | $ 50,000 |  |  |  |  |
AstraZeneca Agreements [Member] | China [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Potential milestone payments | 348,500 |  | 22,000 |  |  |  |
Aggregate consideration received |  |  |  | $ 77,200 |  |  |
Transaction price and allocated to performance obligations |  |  | $ 22,000 |  |  |  |
Proceeds from upfront, non-contingent and non-refundable payments | 28,200 |  |  |  |  |  |
Commercial sales and other events milestone | 187,500 |  |  |  |  |  |
Estimated joint development extended service period |  |  |  | 2024 |  |  |
AstraZeneca Agreements [Member] | China [Member] | Clinical and Development Milestone [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Potential milestone payments | 15,000 |  |  |  |  |  |
AstraZeneca Agreements [Member] | China [Member] | Regulatory Milestone [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Potential milestone payments | $ 146,000 |  |  |  |  |  |

X
- Definition Amount of aggregate consideration receivable under collaborative arrangement. + References No definition available. + Details
Name: | fgen_CollaborativeArrangementAggregateConsideration
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Commercial sales and other events milestone. + References No definition available. + Details
Name: | fgen_CommercialSalesAndOtherEventsMilestone
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of milestone payments related to commercial sales under the collaborative agreement. + References No definition available. + Details
Name: | fgen_CommercialSalesMilestone
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Development milestone payment received. + References No definition available. + Details
Name: | fgen_DevelopmentMilestonePaymentReceived
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Estimated joint development extended service period. + References No definition available. + Details
Name: | fgen_EstimatedJointDevelopmentExtendedServicePeriod
Namespace Prefix: | fgen_
Data Type: | xbrli:gYearItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the total potential amount of milestone payments related to development, regulatory approval and commercial sales under the collaborative agreement. + References No definition available. + Details
Name: | fgen_PotentialMilestones
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration. + References No definition available. + Details
Name: | fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration. + References No definition available. + Details
Name: | fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Transaction price allocated to performance obligations. + References No definition available. + Details
Name: | fgen_TransactionPriceAllocatedToPerformanceObligations
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (g)(7) -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 10 -Section 05 -Paragraph 5 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320 + Details
Name: | us-gaap_Supplies
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_ClinicalDevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_RegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_DeferredApprovalMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_DevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_NewDrugApplicationSubmissionMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_CN
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |